CTA
CRL icon

Carillon Tower Advisers’s Charles River Laboratories CRL Stock Holding History

Carillon Tower Advisers’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$38.6M Buy
+154,537
New +$36.8M 0.24% 131
2018
Q1 		– Sell
-250,242
Closed -$27.4M – 459
2017
Q4 		$27.4M Buy
+250,242
New +$27.2M 0.29% 130

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Carillon Tower Advisers's CRL Position: Q4 2020 in Review

Carillon Tower Advisers opened a new position in Charles River Laboratories (CRL) in Q4 2020: 154,537 shares worth $38.6M. The stake represents 0.24% of the portfolio and ranks #131 among its holdings. This is a return to the name: Carillon Tower Advisers previously reported a position in CRL as recently as Q4 2017.

Carillon Tower Advisers first reported a position in CRL in Q4 2017 and has held it in 2 quarters since. 539 funds tracked by Wall St. Rank hold CRL as of Q4 2020.

  • Carillon Tower Advisers held 154,537 shares of Charles River Laboratories worth $38.6M as of Q4 2020.
  • Charles River Laboratories was a new Carillon Tower Advisers position in Q4 2020.
  • Charles River Laboratories made up 0.24% of Carillon Tower Advisers's portfolio in Q4 2020, its #131 holding.
  • Carillon Tower Advisers first reported a position in Charles River Laboratories in Q4 2017 and has held it in 2 quarters since.
  • 539 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.